An expert discusses how emerging trial data, particularly from ASCENT-04, are reshaping first-line treatment strategies for PD-L1–positive metastatic triple-negative breast cancer (mTNBC) by ...

Discover a study exploring novel drug combinations and genetic insights transforming advanced bladder cancer treatment.

Gilead is continuing to explore sacituzumab govitecan in other phase 3 trials, including ASCENT-07 (ClinicalTrials.gov Identifier: NCT05840211) for hormone receptor–positive, human epidermal ...

CHICAGO — Sacituzumab govitecan continued to show significant improvement in OS among patients with heavily pretreated metastatic hormone receptor-positive breast cancer, according to final OS ...

CHICAGO -- Treatment with single-agent sacituzumab govitecan (Trodelvy) offered no survival advantage over docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated ...

Sacituzumab govitecan, a Trop-2-directed antibody and topoisomerase inhibitor conjugate, binds to Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38, ...

New therapies in breast cancer, particularly ADCs, present unique safety profiles for nurses to be aware of, according to Erika Hamilton, MD.

Study of sacituzumab govitecan (sg) versus docetaxel in participants with advanced or metastatic non-small cell lung cancer (NSCLC) (EVOKE-01). ClinicalTrials.gov. Updated December 7, 2023.

Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC News provided by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sacituzumab Tirumotecan Approval Gives Further Boost Global TROP2 Antibody Market Says Kuick ResearchDelhi, Dec. 16, 2024 (GLOBE NEWSWIRE) -- The recent approval of sacituzumab tirumotecan in ...

Sacituzumab govitecan combined with pembrolizumab improved progression-free survival in PD-L1–positive metastatic triple-negative breast cancer compared with chemotherapy. Vepdegestrant, a ...

Kelun-Biotech's TROP2 ADC Sacituzumab tirumotecan (sac-TMT) Approved For Marketing By NMPA Of China For 2L+ Advanced or Metastatic TNBC. PR Newswire. CHENGDU, China, Nov. 27, 2024.